Drug Delivery - the Active Substance Olaciib - Atc L01xk01

CzechrepublicTenders notice for Drug Delivery - the Active Substance Olaciib - Atc L01xk01. The reference ID of the tender is 114728558 and it is closing on 19 Mar 2025.

100% Secure Payments

Tender Details

  • Country: Czech Republic
  • Summary: Drug Delivery - the Active Substance Olaciib - Atc L01xk01
  • CZT Ref No: 114728558
  • Deadline: 19 Mar 2025
  • Competition: ICB
  • Financier: Self Financed
  • Purchaser Ownership: Public
  • Tender Value: 112625496
  • Notice Type: Tender
  • Document Ref. No.: 98411-2025
  • Purchaser's Detail :
  • Purchaser : FACULTY THOMAYER HOSPITAL
    Address: Vienna 800
    Town: Prague
    NUTS-CODE: CZ010
    Postal Code: 14000
    Phone: +420 261083507
    Email :pavla.klimankova@ftn.cz

  • Description :
  • The subject of the public contract is continuous supplies of a medicinal product containing the active substance OLACIIB - ATC L01XK01.
    LL - OLACIIB, pharmaceutical form 150mg TBL FLM 56, specific unit 56x150mg, drug form 100mg TBL FLM 56, specific unit 56x100mg drugs - the active substance OLACIIB
  • Documents :
  •  Tender Notice

If you are registered member, kindly login to view full details of this tender notice:

CLICK HERE TO LOGIN
CzechrepublicTenders Features

CzechrepublicTenders Features

Fresh and verified Tenders from Czechia. Find, search and filter Tenders/Call for bids/RFIs/RFPs/RFQs/Auctions published by the government, public sector undertakings (PSUs) and private entities.

  • 1,000+ Tenders
  • Verified Tenders Only
  • Accurate Tender Information
  • New Tenders Every Day
  • Consultants for RFI/RFP/RFQ
  • Search, sort, and filter Tenders
  • Customer Support
  • Publish your Tenders
  • Consulting Services
  • Export data to Excel or CRM

Get A Call From Tender Experts

Fill out the form below and you will receive a call from us within 24 hours.

Thank You for Contacting ZimbabweTenders !!
Email Id is already exist !!
Invalid Captcha !

Get FREE SAMPLE TENDERS from Czechia in your email inbox.

  Chat with us